Atria Wealth Solutions Inc. boosted its stake in VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 336.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 14,388 shares of the company’s stock after acquiring an additional 11,088 shares during the period. Atria Wealth Solutions Inc.’s holdings in VanEck Pharmaceutical ETF were worth $1,149,000 as of its most recent filing with the SEC.
Several other hedge funds have also added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. bought a new stake in shares of VanEck Pharmaceutical ETF in the fourth quarter valued at approximately $34,000. JPMorgan Chase & Co. bought a new stake in shares of VanEck Pharmaceutical ETF in the fourth quarter valued at approximately $46,000. Citigroup Inc. raised its position in shares of VanEck Pharmaceutical ETF by 554.0% in the fourth quarter. Citigroup Inc. now owns 1,308 shares of the company’s stock valued at $102,000 after purchasing an additional 1,108 shares during the period. Meitav Investment House Ltd. bought a new stake in shares of VanEck Pharmaceutical ETF in the second quarter valued at approximately $106,000. Finally, Cetera Advisor Networks LLC bought a new stake in shares of VanEck Pharmaceutical ETF in the fourth quarter valued at approximately $210,000.
VanEck Pharmaceutical ETF Stock Up 0.1 %
NASDAQ PPH opened at $87.38 on Tuesday. The company’s 50 day moving average is $83.12 and its 200-day moving average is $80.91. The firm has a market cap of $453.50 million, a P/E ratio of 16.59 and a beta of 0.72. VanEck Pharmaceutical ETF has a 12-month low of $73.40 and a 12-month high of $88.13.
VanEck Pharmaceutical ETF Dividend Announcement
VanEck Pharmaceutical ETF Company Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
- Five stocks we like better than VanEck Pharmaceutical ETF
- How to Invest in the Healthcare Sector
- 3 attractive stocks that insiders are buying
- Canadian Penny Stocks: Can They Make You Rich?
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.